"41322" . "Randomizovan\u00E9, dvojit\u011B zaslepen\u00E9 klinick\u00E9 hodnocen\u00ED f\u00E1ze II hodnot\u00EDc\u00ED \u00FA\u010Dinnost a bezpe\u010Dnost PF-04171327 (denn\u00ED d\u00E1vka 1, 5, 10, 15 mg) ve srovn\u00E1n\u00ED s denn\u00ED d\u00E1vkou 5 mg a 10 mg prednisonu a s placebem u pacient\u016F s revmatoidn\u00ED artritidou po dobu 8 t\u00FDdn\u016F n\u00E1sledovan\u00FDch 4 t\u00FDdny postupn\u00E9ho sni\u017Eov\u00E1n\u00ED d\u00E1vky hodnocen\u00E9ho l\u00E9\u010Div\u00E9ho p\u0159\u00EDpravku. Srovn\u00E1n\u00ED \u00FA\u010Dinnosti a bezpe\u010Dnosti PF 04171327 (1, 5, 10 mg, 15 mg jednou denn\u011B) a 5 mg prednisonu denn\u011B, 10 mg denn\u011B prednison a placebo,po dobu 8 t\u00FDdn\u016F u pacient\u016F s aktivn\u00ED revmatoidn\u00ED artritidou na stabiln\u00ED pozad\u00ED MTX" . . "Praha" . . "Randomizovan\u00E9, dvojit\u011B zaslepen\u00E9 klinick\u00E9 hodnocen\u00ED f\u00E1ze II hodnot\u00EDc\u00ED \u00FA\u010Dinnost a bezpe\u010Dnost PF-04171327 (denn\u00ED d\u00E1vka 1, 5, 10, 15 mg) ve srovn\u00E1n\u00ED s denn\u00ED d\u00E1vkou 5 mg a 10 mg prednisonu a s placebem u pacient\u016F s revmatoidn\u00ED artritidou po dobu 8 t\u00FDdn\u016F n\u00E1sledovan\u00FDch 4 t\u00FDdny postupn\u00E9ho sni\u017Eov\u00E1n\u00ED d\u00E1vky hodnocen\u00E9ho l\u00E9\u010Div\u00E9ho p\u0159\u00EDpravku. Srovn\u00E1n\u00ED \u00FA\u010Dinnosti a bezpe\u010Dnosti PF 04171327 (1, 5, 10 mg, 15 mg jednou denn\u011B) a 5 mg prednisonu denn\u011B, 10 mg denn\u011B prednison a placebo,po dobu 8 t\u00FDdn\u016F u pacient\u016F s aktivn\u00ED revmatoidn\u00ED artritidou na stabiln\u00ED pozad\u00ED MTX"@cs . "Pfizer spol s.r.o." . "1"^^ . "RHEUMATOID ARTHRITIS"@en . "A PHASE 2, RANDOMIZED, DOUBLE-BLIND ASSESSMENT OF EFFICACY AND SAFETY OF PF-04171327(1, 5, 10, 15 MG DOSE, DAILY) COMPARED TO 5 MG AND 10 MG PREDNISONE DAILY AND PLACEBO DAILY IN SUBJECTS WITH RHEUMATOID ARTHRITIS OVER AN 8 WEEK PERIOD FOLLOWED BY A 4 WEEK PERIOD OF TAPERING OF STUDY DRUG"@en . . . "1"^^ . . . "[D1CCD4157A53]" . "RIV/00064190:_____/14:#0000727" . "N" . . "Kopsa, Petr" . . "A PHASE 2, RANDOMIZED, DOUBLE-BLIND ASSESSMENT OF EFFICACY AND SAFETY OF PF-04171327(1, 5, 10, 15 MG DOSE, DAILY) COMPARED TO 5 MG AND 10 MG PREDNISONE DAILY AND PLACEBO DAILY IN SUBJECTS WITH RHEUMATOID ARTHRITIS OVER AN 8 WEEK PERIOD FOLLOWED BY A 4 WEEK PERIOD OF TAPERING OF STUDY DRUG"@en . . . "Randomizovan\u00E9, dvojit\u011B zaslepen\u00E9 klinick\u00E9 hodnocen\u00ED f\u00E1ze II hodnot\u00EDc\u00ED \u00FA\u010Dinnost a bezpe\u010Dnost PF-04171327 (denn\u00ED d\u00E1vka 1, 5, 10, 15 mg) ve srovn\u00E1n\u00ED s denn\u00ED d\u00E1vkou 5 mg a 10 mg prednisonu a s placebem u pacient\u016F s revmatoidn\u00ED artritidou po dobu 8 t\u00FDdn\u016F n\u00E1sledovan\u00FDch 4 t\u00FDdny postupn\u00E9ho sni\u017Eov\u00E1n\u00ED d\u00E1vky hodnocen\u00E9ho l\u00E9\u010Div\u00E9ho p\u0159\u00EDpravku"@cs . . "A TRIAL TO TEST THE EFFICACY AND SAFETY OF STUDY DRUG PF-04171327(1,5,10, 15 MG DOSE, DAILY) COMPARED TO 5 MG AND 10 MG PREDNISONE DAILY AND PLACEBO DAILY FOR SUBJECTS WITH RHEUMATOID ARHTRITIS OVER A PERIOD OF 8 WEEKS FOLLOWED BY 4 WEEKS OF TAPERING OF STUDY DRUG. To compare efficacy and safety of PF 04171327 (1, 5, 10 mg, 15 mg once daily) to 5 mg daily prednisone, 10 mg daily prednisone and placebo given over 8 weeks, in subjects with active RA on a stable background of MTX"@en . "4"^^ . "Randomizovan\u00E9, dvojit\u011B zaslepen\u00E9 klinick\u00E9 hodnocen\u00ED f\u00E1ze II hodnot\u00EDc\u00ED \u00FA\u010Dinnost a bezpe\u010Dnost PF-04171327 (denn\u00ED d\u00E1vka 1, 5, 10, 15 mg) ve srovn\u00E1n\u00ED s denn\u00ED d\u00E1vkou 5 mg a 10 mg prednisonu a s placebem u pacient\u016F s revmatoidn\u00ED artritidou po dobu 8 t\u00FDdn\u016F n\u00E1sledovan\u00FDch 4 t\u00FDdny postupn\u00E9ho sni\u017Eov\u00E1n\u00ED d\u00E1vky hodnocen\u00E9ho l\u00E9\u010Div\u00E9ho p\u0159\u00EDpravku" . . "Randomizovan\u00E9, dvojit\u011B zaslepen\u00E9 klinick\u00E9 hodnocen\u00ED f\u00E1ze II hodnot\u00EDc\u00ED \u00FA\u010Dinnost a bezpe\u010Dnost PF-04171327 (denn\u00ED d\u00E1vka 1, 5, 10, 15 mg) ve srovn\u00E1n\u00ED s denn\u00ED d\u00E1vkou 5 mg a 10 mg prednisonu a s placebem u pacient\u016F s revmatoidn\u00ED artritidou po dobu 8 t\u00FDdn\u016F n\u00E1sledovan\u00FDch 4 t\u00FDdny postupn\u00E9ho sni\u017Eov\u00E1n\u00ED d\u00E1vky hodnocen\u00E9ho l\u00E9\u010Div\u00E9ho p\u0159\u00EDpravku"@cs . "RIV/00064190:_____/14:#0000727!RIV14-MZ0-00064190" . . "Randomizovan\u00E9, dvojit\u011B zaslepen\u00E9 klinick\u00E9 hodnocen\u00ED f\u00E1ze II hodnot\u00EDc\u00ED \u00FA\u010Dinnost a bezpe\u010Dnost PF-04171327 (denn\u00ED d\u00E1vka 1, 5, 10, 15 mg) ve srovn\u00E1n\u00ED s denn\u00ED d\u00E1vkou 5 mg a 10 mg prednisonu a s placebem u pacient\u016F s revmatoidn\u00ED artritidou po dobu 8 t\u00FDdn\u016F n\u00E1sledovan\u00FDch 4 t\u00FDdny postupn\u00E9ho sni\u017Eov\u00E1n\u00ED d\u00E1vky hodnocen\u00E9ho l\u00E9\u010Div\u00E9ho p\u0159\u00EDpravku" .